
Hoth Therapeutics (HOTH) Stock Forecast & Price Target
Hoth Therapeutics (HOTH) Analyst Ratings
Bulls say
Hoth Therapeutics Inc. is advancing its clinical-stage biopharmaceutical portfolio, with promising developments reported for its lead candidate HT-001, which achieved a 100% efficacy rate in reducing skin toxicity and enhancing quality of life in patients during an open-label trial. The company’s strategic initiatives to enhance clinical adoption could strengthen its regulatory positioning and support future submissions based on comprehensive patient data. Additionally, positive interim results from the Phase 2a CLEER-001 trial further underscore HT-001's safety profile and its potential for significant market impact, particularly in oncology and related fields.
Bears say
Hoth Therapeutics Inc. is a clinical-stage biopharmaceutical company that is engaged in developing therapies for various unmet medical needs; however, the company's reliance on multiple developmental assets in early stages presents a significant financial risk due to the potential for prolonged research and development timelines. Furthermore, the lack of revenue generation from approved products raises concerns regarding the company's ability to finance its operations and fund ongoing clinical trials without incurring additional debt or diluting shareholder equity. Additionally, the competitive landscape within the biopharmaceutical sector, coupled with the uncertainties surrounding regulatory approvals and market acceptance of its therapies, contributes to a negative outlook regarding Hoth Therapeutics's stock performance.
This aggregate rating is based on analysts' research of Hoth Therapeutics and is not a guaranteed prediction by Public.com or investment advice.
Hoth Therapeutics (HOTH) Analyst Forecast & Price Prediction
Start investing in Hoth Therapeutics (HOTH)
Order type
Buy in
Order amount
Est. shares
0 shares